The impact of the DREAMS partnership on HIV incidence among young women who sell sex in two Zimbabwean cities: results of a non-randomised study.
AIDS
HIV
epidemiology
intervention study
prevention strategies
Journal
BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
11
09
2020
revised:
06
03
2021
accepted:
16
03
2021
entrez:
28
4
2021
pubmed:
29
4
2021
medline:
25
6
2021
Statut:
ppublish
Résumé
Young women who sell sex (YWSS) in Zimbabwe remain at high risk of HIV infection. Effective HIV prevention strategies are needed. Through support to access a combination of evidence-based interventions, including oral pre-exposure prophylaxis (PrEP), the Determined, Resilient, Empowered, AIDS-free, Mentored and Safe (DREAMS) partnership aimed to reduce new HIV infections among adolescent girls and young women by 40% over 24 months. Non-randomised 'plausibility' evaluation, powered to detect a 40% HIV incidence difference between DREAMS and non-DREAMS sites. Two large cities with DREAMS funding were included, and four smaller non-DREAMS towns for comparison. In all sites, YWSS were enrolled to a cohort through peer-referral. Women were followed up for 24 months. HIV seroconversion was the primary outcome, with secondary outcomes identified through a theory of change. Outcomes were compared between YWSS recruited in DREAMS cities and non-DREAMS towns, adjusting for individual-level confounders and HIV prevalence at enrolment. From April to July 2017, 2431 women were enrolled, 1859 of whom were HIV negative at enrolment; 1019 of these women (54.8%) were followed up from March to May 2019 and included in endline analysis. Access to clinical services increased, but access to socioeconomic interventions promoted by DREAMS was limited. A total of 79 YWSS HIV seroconverted, with HIV incidence among YWSS in DREAMS cities lower (3.1/100 person-years) than in non-DREAMS towns (5.3/100 person-years). In prespecified adjusted analysis, HIV incidence was lower in DREAMS cities but with weak statistical evidence (adjusted rate ratio (RR)=0.68; 95% CI 0.40 to 1.19; p=0.18). Women in DREAMS cities were more likely to report ever and ongoing PrEP use, consistent condom use, fewer sexual partners and less intimate partner violence. It is plausible that DREAMS lowered HIV incidence among YWSS in two Zimbabwean cities, but our evaluation provides weak statistical evidence for impact and suggests any reduction in incidence was lower than the anticipated 40% decline. We identified changes to some important 'pathways to impact' variables, including condom use.
Identifiants
pubmed: 33906844
pii: bmjgh-2020-003892
doi: 10.1136/bmjgh-2020-003892
pmc: PMC8088246
pii:
doi:
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Lancet Glob Health. 2020 Feb;8(2):e264-e275
pubmed: 31924539
BMC Public Health. 2018 Jul 25;18(1):912
pubmed: 30045711
AIDS Care. 2016 Mar;28 Suppl 2:14-20
pubmed: 27391994
PLoS One. 2018 Mar 15;13(3):e0194301
pubmed: 29543858
PLoS One. 2018 Dec 13;13(12):e0208243
pubmed: 30543640
BMC Med Res Methodol. 2019 Oct 29;19(1):202
pubmed: 31664912
J Acquir Immune Defic Syndr. 2019 May 1;81(1):24-35
pubmed: 30964804
Lancet Infect Dis. 2012 Jul;12(7):538-49
pubmed: 22424777
BMC Public Health. 2018 Jan 31;18(1):203
pubmed: 29386001
Curr Opin Infect Dis. 2019 Feb;32(1):24-30
pubmed: 30461452
PLoS One. 2018 Dec 26;13(12):e0208689
pubmed: 30586376
J Int AIDS Soc. 2020 Mar;23(3):e25463
pubmed: 32144874
PLoS One. 2020 Jan 13;15(1):e0226062
pubmed: 31929547
PLoS Med. 2017 Nov 21;14(11):e1002444
pubmed: 29161256
Int J Epidemiol. 2018 Feb 1;47(1):236-245
pubmed: 29024978
AIDS Behav. 2011 Jul;15(5):959-69
pubmed: 20844946
J Infect Dis. 2020 Jun 03;:
pubmed: 32492704
J Acquir Immune Defic Syndr. 2013 May 1;63(1):126-34
pubmed: 23337368
BMC Public Health. 2019 Oct 30;19(1):1417
pubmed: 31666043
J Int AIDS Soc. 2020 May;23(5):e25476
pubmed: 32406983
J R Stat Soc Ser A Stat Soc. 2015 Jan;178(1):241-269
pubmed: 27226702
BMC Public Health. 2020 May 29;20(1):806
pubmed: 32471410
J Int AIDS Soc. 2015 Sep 14;18:20088
pubmed: 26374604
Int J Epidemiol. 1999 Feb;28(1):10-8
pubmed: 10195658
J Int AIDS Soc. 2019 Jul;22 Suppl 4:e25320
pubmed: 31328445
J Int AIDS Soc. 2019 Dec;22(12):e25410
pubmed: 31793748
BMC Public Health. 2016 Jul 29;16:660
pubmed: 27473180
J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):141-148
pubmed: 31513552